Publications by authors named "R J Haynes"

Introduction: Haemodynamic atrioventricular delay (AVD) optimisation has primarily focussed on signals that are not easy to acquire from a pacing system itself, such as invasive left ventricular catheterisation or arterial blood pressure (ABP). In this study, standard clinical central venous pressure (CVP) signals are tested as a potential alternative.

Methods: Sixteen patients with a temporary pacemaker after cardiac surgery were studied.

View Article and Find Full Text PDF

Chatbots are artificial intelligence (AI) programs designed to simulate conversations with humans that present opportunities and challenges in scientific research. Despite growing clarity from publishing organisations on the use of AI chatbots, researchers' perceptions remain less understood. In this international cross-sectional survey, we aimed to assess researchers' attitudes, familiarity, perceived benefits, and limitations related to AI chatbots.

View Article and Find Full Text PDF

Patients with chronic kidney disease (CKD) are at risk of progressive loss of kidney function, heart failure, and cardiovascular death despite current proven therapies, including renin-angiotensin system inhibitors (RASi), sodium glucose co-transporter-2 inhibitors (SGLT2i), and statin-based regimens. RASi and SGLT2i reduce risk of CKD progression irrespective of primary cause of kidney disease, suggesting they target final common pathways. Targeting aldosterone overactivity with a nonsteroidal mineralocorticoid receptor antagonist (MRA) also reduces cardiorenal risk in patients with albuminuric diabetic kidney disease already treated with RASi.

View Article and Find Full Text PDF
Article Synopsis
  • The EMPA-KIDNEY trial examined the effects of empagliflozin, an SGLT2 inhibitor, on patients with chronic kidney disease at risk for progression, assessing outcomes during and after the trial.
  • A total of 6609 patients were randomized, with 4891 participating in a follow-up period after the trial where they were observed for an additional 2 years, without trial medication but allowed to use other SGLT2 inhibitors.
  • Results showed that fewer primary outcome events (like kidney disease progression or cardiovascular death) occurred in the empagliflozin group (26.2%) compared to the placebo group (30.3%), suggesting lasting benefits of the drug even after the trial ended. *
View Article and Find Full Text PDF

Bauxite processing residue produced at an Alumina refinery was used to produce manufactured soil. The residue was first acidified and then leached to remove excess salts. Green waste compost was added at rates of 5 and 10 % w/w, with or without the addition of 20 % w/w dune sand.

View Article and Find Full Text PDF